Latest Articles

Publication Date
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Sahm

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Sahm

Published: July 16, 2026, 10:27 a.m.
Adjunctive vitamin D supplementation in women receiving dienogest therapy for endometriosis: a randomized controlled trial.

Endometriosis is a chronic, estrogen-dependent inflammatory disease that causes debilitating pain and significantly impairs quality of life. Due to its anti-inflammatory and immunomodulatory properties, vitamin D has been proposed as …

Published: July 16, 2026, midnight
Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype - londoninsider.co.uk

Merck's (MRK) Keytruda Becomes First PD-1 Inhibitor To Beat Chemotherapy Alone In Endometrial Cancer Subtype londoninsider.co.uk

Published: July 15, 2026, 11:49 p.m.
Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer - Benzinga

Merck Says Blockbuster Keytruda Outperforms Chemotherapy in Advanced Endometrial Cancer Benzinga

Published: July 15, 2026, 5:25 p.m.
GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline - TipRanks

GSK Advances New Maintenance Therapy Trial in Endometrial Cancer, Adding Depth to Its Oncology Pipeline TipRanks

Published: July 15, 2026, 4:46 p.m.
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer - OncLive

Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer OncLive

Published: July 15, 2026, 3:58 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - BioSpace

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy BioSpace

Published: July 15, 2026, 3:11 p.m.
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy - Business Wire

KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy Business Wire

Published: July 15, 2026, 10:45 a.m.
Surgical management of endometriosis: surgical techniques, adjuvant therapy, and long-term management Number 10 - 2026.

• Surgical outcomes in endometriosis vary substantially according to disease phenotype, symptom profile, and reproductive priorities. • Excisional surgery for ovarian endometriomas is associated with lower recurrence rates but carries …

Published: July 15, 2026, midnight
Beyond growing teratoma syndrome: post-treatment manifestations and diagnostic challenges following ovarian immature teratoma.

Growing teratoma syndrome (GTS) is a rare condition classically associated with platinum-based chemotherapy for malignant ovarian germ cell tumors. However, post-treatment findings following ovarian immature teratoma may represent a broader …

Published: July 14, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!